Pharmaceuticals
First patient treated in Clarity's therapeutic prostate cancer trial
Highlights * Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)[1] investigating Targeted Copper Theranostics (TCTs) in patients with metastatic castrate-resistant prostate cancer (mCRPC) ...
2022-10-07 21:06
2626
HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner
* Immunovant, a HanAll's licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL161ANS (also known as IMVT-1402) * In animal studies, HL161ANS indicated deep IgG reductions similar to batoclimab with no or minimal impact on albumin and LDL cholesterol level * Batoclimab (form...
2022-10-04 19:00
2220
Hayashibara Brings Back "Trehalose Symposium" to Reveal Its Game-changing Versatilities in Human Biochemistry
OKAYAMA, Japan, Oct. 4, 2022 /PRNewswire/ -- Hayashibara Co., Ltd., a member of Nagase Group and headquartered in Okayama City, westernJapan, hosted the 24th Trehalose Symposium, with the support of the Japanese Society of Applied Glycoscience, onSeptember 8, 2022. Photo: https://kyodonewsprwir...
2022-10-04 14:00
1742
AeroRx Partners with HCmed to Develop a Nebulized LABA/LAMA Combination Solution for the Treatment of Chronic Obstructive Pulmonary Disease
TAIPEI, Oct. 2, 2022 /PRNewswire/ -- AeroRx Therapeutics, LLC. (AeroRx) and HCmed Innovations Co., Ltd. (HCmed) have initiated a collaboration, introducing a LABA/LAMA combination solution for delivery with a breath-actuated nebulizer. This collaboration sets forth the framework by which both com...
2022-10-03 09:00
2155
Qilian International Holding Group Limited Reports Financial Results for the First Six Months of Fiscal Year 2022
JIUQUAN, China, Sept. 30, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), aChina-based pharmaceutical and chemical products manufacturer, today announced its unaudited financial results for the first six months of fiscal year 2022 endedMarch 31, 2022...
2022-10-01 04:30
5739
Samsung Biologics introduces new development platforms S-DUAL™ and DEVELOPICK™ at BPI Boston 2022
* Two distinctive platforms will streamline the antibody development process. * With an advanced design and high binding affinity, S-DUAL™ ensures optimized manufacturability of bispecific antibodies. * DEVELOPICK™ provides early insight and selection guidance to save time and cost to maxi...
2022-09-29 19:00
2222
NeuShen Therapeutics Closes Pre-A Financing with ~$20M
* Closure of pre-A financing round led by LAMPAM Capital * Dual internal discovery platforms of small molecule and AAV-based gene therapy targeting neurological and psychiatric disorders SHANGHAI, Sept. 29, 2022 /PRNewswire/ -- NeuShen Therapeutics, Inc., a biotechnology company focusing on d...
2022-09-29 17:50
2644
Kintor Pharma Announces Publication of Phase Ib Data from Pruxelutamide for AR+ mBC in EJC
SUZHOU, China, Sept. 29, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the results from a phase Ib study of pruxelutamide (used to be ...
2022-09-29 14:22
2191
Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc
* Simcere will receive a $15 million upfront payment, and up to $492 million in development and commercial milestone payments considering successful achievements in several indications, with an important part as sales milestones, as well as up to low double-digit tiered royalties based upon fu...
2022-09-29 11:32
2578
Zhongchao Inc. Establishes Chongqing Xinjiang Pharmaceutical Co., Ltd. to Improve Patient Access to Medications
SHANGHAI, Sept. 28, 2022 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced the establishment of Chongqing Xinjiang Pharmaceutical Co., Ltd...
2022-09-28 21:18
2266
Samsung Biologics Earns Gold Rating from EcoVadis for Its Sustainability Efforts
* Rising from last year's ranking, the company's united effort and dedication to integrating sustainable practices in all areas of its business drew recognition from EcoVadis, which provided high marks in responsible procurement and environmental management. * More than 100,000 companies from...
2022-09-28 19:00
2146
Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Sept. 27, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announces that it has completed the first subject dosing in a phase I study of HBM9378 (or SKB378 as referred to by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd...
2022-09-27 21:40
2198
Angel Pharmaceuticals Announces Approval of IND Application for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China
JIAXING,China and BURLINGAME,Calif., Sept. 26, 2022 /PRNewswire/ -- Angel Pharmaceuticals Ltd. ("Angel Pharma"), a clinical-stage biopharmaceutical company,today announced that the IND application for mupadolimab (formerly CPI-006) has been approved by the Center for Drug Evaluation (CDE) to init...
2022-09-27 08:30
2038
Fosun Pharma and MAIA Pharmaceuticals Jointly Announce the Successful Commercialization of Only FDA Approved 20ml Sodium Phenylacetate and Sodium Benzoate (SPSB) Liquid Product
PRINCETON, N.J., Sept. 26, 2022 /PRNewswire/ -- Shanghai Fosun Pharma (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH; 02196.HK) today announced that the 20 ml, Sodium Phenylacetate and Sodium Benzoate (SPSB) liquid product, which is under an exclusive partnership betweenFosun Pharma USA...
2022-09-26 22:13
2411
Bioheng Biotech Announces Publication of Impressive Results with CD7-targeted allogeneic CAR-T cell therapy for Relapsed or Refractory T Cell Malignancies
NANJING and HANGZHOU, China, Sept. 26, 2022 /PRNewswire/ -- Nanjing Bioheng Biotech Co., Ltd, a clinical-stage biotechnology company focused on developing novel cellular immunotherapy, today announced that a phase I clinical study results of RD13-01, an anti-CD7 universal CAR-T therapy product, h...
2022-09-26 21:00
2371
PharmAbcine to Participate in BIO-Europe 2022
DAEJEON, South Korea, Sept. 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will participate in the upcoming BIO-Europe 2022 which will take place ...
2022-09-26 20:00
2325
WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility
New facility expands integrated drug product R&D and manufacturing services to global customers SHANGHAI, Sept. 26, 2022 /PRNewswire/ -- WuXi STA, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of its first high potency (HP) o...
2022-09-26 20:00
2613
CellOrigin Biotech Announces Global Strategic Collaboration with Qilu Pharma to Develop "Off-the-Shelf" CAR-iMAC Cell Therapy
HANGZHOU, China, Sept. 26, 2022 /PRNewswire/ -- CellOrigin Biotech (Hangzhou) Co., Ltd. announced it has made a global strategic collaboration agreement with Qilu Pharma to develop, manufacture and commercialize proprietary "off-the-shelf" induced pluripotent stem cell- (iPSC) derived Chimeric An...
2022-09-26 12:31
2263
111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
SHANGHAI, Sept. 23, 2022 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), consisting of three independent directors, Mr.Jian Sun, who is the chairman...
2022-09-23 12:30
2711
RVAC Medicines Initiates First-in-Human Clinical Trials for mRNA COVID-19 Vaccine Candidates
SINGAPORE, Sept. 21, 2022 /PRNewswire/ -- RVAC Medicines Pte. Ltd., a messenger RNA (mRNA) technology platform company incubated by CBC Group in 2021, announced today that a participant has been dosed in a Phase 1, first-in-human study evaluating the company's mRNA-based COVID-19 vaccine candidat...
2022-09-22 10:00
2333
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21CHANDO Group Presents 20 Research Papers at IFSCC 2026 Congress in Perth
[Picked up by 260 media titles]
2026-10-06 11:40
Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
9459
DayOne Files Registration Statement for Proposed Initial Public Offering
2026-10-06 05:28
9058
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
8596
